Notably, ramucirumab, an antibody targeting VEGFR2 (14), and apatinib, a VEGFR2 tyrosine kinase inhibitor (TKIs) (15), have shown survival benefits in advanced GC. The gene discussed is KDR; the disease is gastric cancer.